Press Releases

CAR T-Cell Therapy Market – Size, Scope, Forecast to – 2027

Share This Article

Latest Study on “CAR T-Cell Therapy Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2027”.

The global CAR T-Cell Therapy market size is expected to be worth around US$  20.4 billion by 2027, according to a new report by Nova One Advisor .

The global CAR T-Cell Therapy market size was valued at US$ 1.7  billion in 2020 and is anticipated to grow at a CAGR of  29.1% during forecast period 2021 to 2027.

Get your Customized Research Report@https://www.novaoneadvisor.com/report/customization/6000

Growth Factors:

CAR T-cell therapy is a recently approved treatment option for various types of cancer. CAR T cell therapy is provided by removing or harvesting T cells from a patient with cancer, transfecting the cells with CAR genes that are directed against the patient’s tumor type, expanding the modified T cell population, and reinfusing the cells back into the patient. Currently, Kymriah, Yescarta, Tecartus, Breyanzi, and ABECMA are the CAR T-cell therapy approved products for acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others.

The global CAR T-cell therapy market is driven by increase in incidence of cancer and strong product pipeline. North America dominated the global CAR T-cell therapy market in 2020 and the trend is anticipated to continue during the forecast period. Highly structured healthcare industry, early adoption of new products, high prevalence rate of cancer, and presence of major players are expected to propel the CAR T-cell therapy market in North America. Asia Pacific is likely to be a highly lucrative market for CAR T-cell therapy during the forecast period. The market in the region is projected to expand at a high CAGR from 2021 to 2027.

Increase in incidence of cancer and strong product pipeline are anticipated to boost the growth of the global CAR T-cell therapy market. According to the WHO, one in five people develop cancer during their lifetime, and one in eight men and one in 11 women die from the disease. These new estimates suggest that more than 50 million people are living within five years of a past cancer diagnosis. According to the WHO, in 2020, around 544,352 new cases of non-Hodgkin lymphoma were recorded globally.

Strong product pipeline is a major factor driving the demand for CAR T-cell therapy products. For instance, Autolus Therapeutics plc has one innovative product, AUTO1, in phase I trial for treatment of adult acute lymphoblastic leukemia. AUTO1 contains obecabtagene autoleucel, which is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies.

Report Scope of the CAR T-Cell Therapy Market

Report Scope Details
Market Size USD 20.4 Billion by 2027
Growth Rate CAGR of 8.7% From 2021 to 2027
Base Year 2020
Forecast Period 2021 to 2027
Historic Data 2017 to 2020
Report coverage Growth Factors, Revenue Status, Competitive Landscape,  and Future Trends
Segments Covered Product Type, Indication,End-user and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Companies Mentioned Pfizer, Inc., Novartis AG, Bristol-Myers Squibb, Amgen, Inc., Sorrento Therapeutics, Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Merck & Co., Inc., and bluebird bio, Inc..

Market Segmentation analysis:

In terms of product type, the global CAR T-cell therapy market has been classified into axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, and others

Based on indication, the global CAR T-cell therapy market has been categorized into acute lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, multiple myeloma, and others

In terms of end-user, the global CAR T-cell therapy market has been divided into hospitals and cancer treatment centers

Each of the segments has been analyzed in detail for CAR T-cell therapy trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The CAR T-cell therapy market report provides current and future revenue (US$ Mn) for each of these segments for the period from 2017 to 2027, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2027 along with market size estimations.

Regional analysis:

In terms of region, the global CAR T-cell therapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global CAR T-cell therapy market in 2020, followed by Europe. North America’s large market share can be ascribed to technologically advanced research and treatment platforms, increase in number of cancer patients, new product launches, and presence of major players. The CAR T-cell therapy market in Asia Pacific is anticipated to expand at a high CAGR from 2021 to 2027. This can be ascribed to the presence of developing countries with commercial hubs, expansion of business organizations, rise in awareness about CAR T-cell therapy, improvement in healthcare infrastructure, and increase in investments by companies.

COVID-19 Impact on CAR T-Cell Therapy Sales

  • Businesses today are operating in a dynamic environment. Earlier focus primarily concentrated on keeping pace with changing consumer preferences. COVID-19 outbreak was unprecedented and exposed vulnerabilities of various industries. Pandemic-induces obstacles also were registered in the CAR T-Cell Therapy market.
  • Sales plummeted as COVID-19 gradually tightened its noose worldwide. Supply-chain disruptions caused massive losses, while demand took nose-dive as consumers remained indoors with affected countries implementing either partial or complete lockdown.
  • Gradual recovery however is on the cards with the roll out of vaccinations. Nonetheless, consecutive waves of the virus compelled businesses to stay prepared for the worst. As government and healthcare organizations successfully implement steps to contain the spread of COVID-19, industries have begun operations, albeit at a slow and more cautious pace.
  • Against this backdrop, Nova one advisor’s study predicts gradual recovery for the CAR T-Cell Therapy market 2021 onwards. This trend will however continue through the course of the report’s assessment period

Download This Full Research Report (Single User License US$ 3500)@https://www.novaoneadvisor.com/report/checkout/6000

Recent report on the CAR T-Cell Therapy market, with the help of a comprehensive outlook, provides readers with an assessment of the global market landscape. This study on the CAR T-Cell Therapy market analyzes the scenario for the period of 2017 to 2027, wherein, 2021 is the base year and 2020 is historical data. This report enables readers to make important decisions with regard to their business, with the help of a wealth of Information enclosed in the study. The report also provides the compound annual growth rate (CAGR) of the global CAR T-Cell Therapy market for the forecast period of 2021–2027. This data can help readers interpret quantitative growth aspects of the global market during the forecast period. It presents a wealth of information on key market dynamics, including drivers, market trends, and challenges, as well as the structure of the global market across the globe.

The report analyzes the historical and present-day scenario of the global CAR T-Cell Therapy market to accurately gauge its growth potential. The study presents detailed information about important growth factors, restraints, and key trends that are creating the landscape for growth of the global market in order to identify opportunities for stakeholders.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the CAR T-Cell Therapy market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the market.

The report delves into the competition landscape of the global CAR T-Cell Therapy market. Key players operating in the market have been identified and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the CAR T-Cell Therapy market that are profiled in this report.

Y-o-Y growth comparison, volume and revenue comparison, and market share comparison of various market segments are provided in the report. The CAR T-Cell Therapy market is analyzed at both regional and country levels.

Key Players:

This report provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the CAR T-Cell Therapy market and ranks noticeable companies as per their occurrence in diverse regions across globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.

Some of the prominent players in the CAR T-cell Therapy Market include:  Pfizer, Inc., Novartis AG, Bristol-Myers Squibb, Amgen, Inc., Sorrento Therapeutics, Inc., Johnson & Johnson Services, Inc., Gilead Sciences, Inc., Merck & Co., Inc., and bluebird bio, Inc.

Segments Covered in the Report

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2027 and covers subsequent region in its scope:

Market: Segmentation

  • CAR T-cell Therapy Market, by Product Type
    • Axicabtagene Ciloleucel
    • Tisagenlecleucel
    • Brexucabtagene Autoleucel
    • Lisocabtagene Maraleucel
    • Idecabtagene Vicleucel
    • Others
  • CAR T-cell Therapy Market, by Indication
    • Acute Lymphocytic Leukemia
    • Diffuse Large B-cell lymphoma
    • Mantle Cell Lymphoma
    • Follicular Lymphoma
    • Multiple Myeloma
    • Others
  • CAR T-cell Therapy Market, by End-user
    • Hospitals
    • Cancer Treatment Centers

 Research Methodology

A unique research methodology has been utilized to conduct a comprehensive research on the growth of the global CAR T-Cell Therapy market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions. Secondary sources referred to by analysts during the production of the global market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.

These primary and secondary sources provided exclusive information during interviews, which serves as a validation from mattress topper industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global CAR T-Cell Therapy market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped to estimates the future prospects of the global market more reliable and accurate.

Key Questions are

  • What are the key factors influencing the CAR T-Cell Therapy market in each region?
  • How much value will the global market generate by the end of the forecast period?
  • What will be the CAGR of the global market between 2021 and 2027?
  • What would be the Y-o-Y growth trend of the global market between 2021 and 2027?
  • What is the future scope and current trends in technologies of the global market?
  • What is the revenue of the global market based on segments?
  • Which key strategies are used by top players of the global market?
  • Which are the leading companies in the global market?
  • What are the essential strategies by key stakeholders in the market to expand their geographic presence?
  • What are the major advancements witnessed in the global market?

Why should you invest in this report?

If you are aiming to enter the global CAR T-Cell Therapy market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for CAR T-Cell Therapy are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2027 so that you can plan your strategies to enter this market accordingly.

Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Purchase Full Research Report (Single User License US$ 3500)@https://www.novaoneadvisor.com/report/checkout/6000

About Us

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@novaoneadvisor.com

Steve Robber

My name is Steve Robber, I’m the Owner of Market Stats News. Steve has served in many positions at various organizations for the past seven years. Currently he is an Author at Finance.Yahoo. Contact us for a free news publication, we look forward to speaking with you!

Related Articles

Back to top button